Form D · Pharmaceuticals
Celator Pharmaceuticals Inc
Princeton, NJ · CIK 0001327467
Offering snapshot reported May 13, 2013 · SEC filing
- Reported sold
- $39.3M Offering amount: $39.3M
- Investors reported
- 306 Form D · investor count
- Minimum accepted
- $22.5K Reported outside-investor minimum
- First sale
- Aug 28, 2012 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$4,148,617 → $39,262,788
- Reported investors106 → 306
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 13, 2013 | Amendment | $39,262,788 | $35,114,171vs Aug 30, 2012 | 306 | SEC filing |
| Aug 30, 2012 | Initial | $4,148,617 | No comparison | 106 | SEC filing |
| Dec 28, 2011 | Initial | $2,576,867 | No comparison | 10 | SEC filing |
| Sep 7, 2010 | Initial | $15,000,001 | No comparison | 12 | SEC filing |
| May 10, 2010 | Initial | $2,500,000 | No comparison | 9 | SEC filing |
| Aug 1, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jul 20, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| May 16, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $3.43M
- Finders' fees
- $0
- Form D file number
- 021-183445
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| National Securities Corporation | 7569 | |
| Roth Capital Partners, LLC | 15407 |
Source: Form D, filed May 13, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Patrick Brady | Director |
| J. Kevin Buchi | Director |
| Kenneth Galbraith | Director |
| Brenda D. Gavin | Director |
| Brenda D Gavin, D.V.M. | Director |
| Scott Jackson | Director, Executive |
| Richard S. Kollender | Director |
| Lawrence Mayer | Executive |
| Joseph A. Mollica | Director |
| Joseph A. Molliica, Ph.D. | Director |
| Scott Morenstein | Director |
| Fred M. Powell | Executive |
| Jackson T. Scott | Director, Executive |
| Nicole Vitullo | Director |
| David Wood | Executive |
| Alex Zisson | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
303 B College Road East
Princeton, NJ, 08540
Princeton, NJ, 08540